R.PR
REGISTERED-PRINCIPAL REGISTER
03/29/2022
Back to search
Official data from USPTO
EBI EXPONENTIAL BIOTHERAPIES
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
70
Latest update
03/29/2022
Trademark type
Combined
Nice classes
5, 40, 42
Filing date
01/22/2018
Registration date
03/29/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/29/2022
Last transaction
03/29/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
3
Owner type
03
Owner location
New York, NY
Examiner
INGRAM,KYLE G
Law office
N70
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of a broken circle comprised of a curved red band and a curved gray band. A red triangle appears in the middle of the left band and protrudes into the circle. Within the left side of the circle are two gray polygons of triangular shape with curved corners and lines. To the right of this circular design are the letters "EBI" appearing in a large gray font with the wording "EXPONENTIAL BIOTHERAPIES" appearing in a smaller gray font below.
Holders and representatives
Holders
Exponential Biotherapies, Inc.
Representatives
HOPE V. SHOVEIN BROOKS KUSHMAN, P.C.
Technical classification
Nice Classes
Class 5Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
medicinesmedicines for alleviating or treating vasculogenic diseasemedicines for alleviating or treating hemodynamic instabilitiesmedicines for alleviating or treating diabetesmedicines for alleviating or treating of immune system related diseases and disorders; pharmaceutical drugspharmaceutical preparations for alleviating or treating vasculogenic diseasepharmaceutical preparations alleviating or treating hemodynamic instabilitiespharmaceutical preparations for alleviating or treating diabetespharmaceutical preparations for alleviating or treating of immune system related diseases and disorders; biopharmaceutical drugsbiopharmaceutical preparations for alleviating or treating vasculogenic diseasebiopharmaceutical preparations for alleviating or treating hemodynamic instabilitiesbiopharmaceutical preparations for alleviating or treating diabetesbiopharmaceutical preparations for alleviating or treating of immune system related diseases and disorders; biopharmaceuticalsbiopharmaceuticals for alleviating or treating vasculogenic diseasebiopharmaceuticals alleviating or treating hemodynamic instabilitiesbiopharmaceuticals for alleviating or treating diabetesbiopharmaceuticals for alleviating or treating of immune system related diseases and disorders; synthetic peptides for biopharmaceutical purposes and for pharmaceutical purposessynthetic peptides for alleviating or treating vasculogenic diseasesynthetic peptides for alleviating or treating hemodynamic instabilitiessynthetic peptides for alleviating or treating diabetessynthetic peptides for alleviating or treating of immune system related diseases and disorders; synthetic peptidemimetics for biopharmaceutical purposes and for pharmaceutical purposessytnthetic peptidomimetics for alleviating or treating vasculogenic diseasesynthetic peptidomimetics for alleviating or treating hemodynamic instabilitiessynthetic peptidomimetics for alleviating or treating diabetessynthetic peptidomimetics for alleviating or treating of immune system related diseases and disorders
Class 40
custom manufacture of medicinespharmaceutical drugsbiopharmaceutical drugspharmaceuticals and biopharmaceuticals; treatment of biopharmaceutical and pharmaceutical materials being medicinesbiopharmaceutical and pharmaceutical compoundssynthetic peptides and synthetic peptidomimetics; processing of medicinesbiopharmaceutical and pharmaceutical compoundssynthetic peptides and synthetic peptidomimetics for others; custom manufacture of medical devices for others
Class 42
biopharmaceutical and pharmaceutical research; conducting clinical trials for others in the fields of medicinessynthetic peptides and synthetic peptidomimetics as they relate to use as an ingredient in medicinesbiopharmaceuticalspharmaceuticalspharmaceutical drugs and biopharmaceutical drugs; scientific research of medicinessynthetic peptides and synthetic peptidomimetics as they relate to use as an ingredient in medicinesbiopharmaceuticals and pharmaceuticalspharmaceutical drugs and biopharmaceutical drugs; developmenttestinginspection of medicinessynthetic peptides and synthetic peptidomimetics as they relate to use as an ingredient in medicinespharmaceutical drugsbiopharmaceutical drugspharmaceuticals and biopharmaceuticals; laboratory services relating to medicinessynthetic peptidessynthetic peptidomimeticspharmaceutical drugsbiopharmaceutical drugspharmaceuticals and biopharmaceuticalsresearch in the fields of medicinessynthetic peptidessynthetic peptidomimeticsbiopharmaceuticalspharmaceuticalspharmaceutical drugs and biopharmaceutical drugs; laboratory analysis in the fields of medicinessynthetic peptidessynthetic peptidomimeticsbiopharmaceuticalspharmaceuticalspharmaceutical drugs and biopharmaceutical drugs; medical research in the fields of medicinessynthetic peptidessynthetic peptidomimeticsbiopharmaceuticalspharmaceuticalspharmaceutical drugs and biopharmaceutical drugs; scientific research for medical purposes in the fields of medicinessynthetic peptidessynthetic peptidomimeticsbiopharmaceuticalspharmaceuticalspharmaceutical drugs and biopharmaceutical drugs
Publications
History of USPTO decisions and trademark events.
70 publications found
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/11/2022
PUBO
PUBLISHED FOR OPPOSITION
01/11/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/22/2021
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
12/07/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/02/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
12/02/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
12/02/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
12/02/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
12/02/2021
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
11/29/2021
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
11/09/2021
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
10/25/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/16/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/13/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/13/2021
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
10/13/2021
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
10/12/2021
GNFR
FINAL REFUSAL E-MAILED
10/12/2021
CNFR
FINAL REFUSAL WRITTEN
10/12/2021
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
10/01/2021
PBSR
WITHDRAWN FROM PUB - SENIOR ATTORNEY REQUEST
10/01/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/01/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/01/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/01/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/01/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/01/2021
GNRT
NON-FINAL ACTION E-MAILED
03/01/2021
CNRT
NON-FINAL ACTION WRITTEN
03/01/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/18/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/18/2021
ALIE
ASSIGNED TO LIE
02/17/2021
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
02/11/2021
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
10/01/2020
GNSL
LETTER OF SUSPENSION E-MAILED
10/01/2020
CNSL
SUSPENSION LETTER WRITTEN
10/01/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/11/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/11/2020
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
09/04/2020
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
08/18/2020
GNSI
INQUIRY TO SUSPENSION E-MAILED
08/18/2020
CNSI
SUSPENSION INQUIRY WRITTEN
08/18/2020
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
08/04/2020
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
01/09/2020
GNSL
LETTER OF SUSPENSION E-MAILED
01/09/2020
CNSL
SUSPENSION LETTER WRITTEN
01/09/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/26/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/26/2019
ALIE
ASSIGNED TO LIE
12/19/2019
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
12/16/2019
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
06/15/2019
GNSI
INQUIRY TO SUSPENSION E-MAILED
06/15/2019
CNSI
SUSPENSION INQUIRY WRITTEN
06/15/2019
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
06/11/2019
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
11/20/2018
GNSL
LETTER OF SUSPENSION E-MAILED
11/20/2018
CNSL
SUSPENSION LETTER WRITTEN
11/20/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/10/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/09/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/09/2018
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/09/2018
GNRT
NON-FINAL ACTION E-MAILED
05/09/2018
CNRT
NON-FINAL ACTION WRITTEN
05/09/2018
DOCK
ASSIGNED TO EXAMINER
05/02/2018
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
02/08/2018
ALIE
ASSIGNED TO LIE
02/07/2018
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
02/03/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/02/2018
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
01/30/2018
NWAP
NEW APPLICATION ENTERED
01/25/2018
Continuous trademark protection
Get notified about every new filing that threatens EBI EXPONENTIAL BIOTHERAPIES or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.